-Data support VCN-01 acceptable safety profile with encouraging biological and clinical activity, and-Data support VCN-01 acceptable safety profile with encouraging biological and clinical activity, andidentify recommended Phase 2 dose (RP2D)-
-Publication further supports the development of Synthetic Biologics’ novel oncolytic adenovirus (OV)platform-
News
News
Follows recent announcement of planned acquisition of VCN Biosciences by Synthetic Biologics.
VCN Biosciences Announces Publication in Peer-Reviewed Journal of Immunotherapy of Cancer on Clinical Data obtained with VCN-01 after intratumorally administration in patients with Pancreatic Cancer
Synthetic Biologics Announces Planned Transformative Acquisition of VCN Biosciences; Developer of a Novel Oncolytic Virus Platform Targeting Pancreatic and other Solid Tumors
Synthetic Biologics Announces Planned Transformative Acquisition of VCN Biosciences; Developer of a Novel Oncolytic Virus Platform Targeting Pancreatic and other Solid TumorsLead drug candidate VCN-01 demonstrated clinical activity in multiple Phase 1 clinical trialsDesigned for systemic delivery, high selectivity, and enhanced tumor accessVCN-01 granted Orphan Drug Designation in Pancreatic Cancer by the EMASynthetic Biologics and VCN Biosciences to host a conference call today, December 14th, at 10:00 a.m. Eastern Time
For Immediate Release
Barcelona, November 2nd, 2021.- VCN Biosciences, a clinical-stage immuno-oncology company focused on the development of the next generation of oncolytic adenoviruses, today announced the oral presentation at the upcoming 2021 International Oncolytic Virus Conference (IOVC) being held November 5-7, 2021, both virtually and in Sedona, Arizona.
Barcelona, February 24, 2021.- VCN Biosciences, a clinical-stage immuno-oncology company focused on the development of the next generation of oncolytic adenoviruses, today announced that VCN-01 at a dose of 3.3x1012 vp/patient can be safely administered in combination with Durbalumab when administered 15 days apart. Accordingly, in an Investigator Meeting, it was decided that VCN-01 will be further investigated at a higher dose of 1x1013 vp/patient in combination with Durvalumab.
Barcelona, March 24, 2021.- VCN Biosciences, a clinical-stage immuno-oncology company focused on the development of the next generation of oncolytic adenoviruses, today announced the publication of preclinical research on promising therapy VCN-11 in Peer-Reviewed Journal of Controlled Release.
Barcelona, November 27, 2020 – A team of researchers from SJD BarcelonaA team of researchers from SJD BarcelonaChildren’s Hospital and the biotechnology company VCN Biosciences, a Grifols company,has developed a world-first treatment which has prevented a child, who hadalready lost an eye to retinal cancer, from losing the other eye and becomingcompletely blind. As a result, Félix, who travelled from Venezuela to Barcelonaspecifically for the treatment, is now disease-free and retains his visual acuity, allowinghim to walk and play just as before. The treatment, which was administered as part ofa clinical trial, consists in injecting a genetically modified virus into the tumour-affectedeye. This virus can select, attack and destroy cancer cells.
September 3, 2019 –VCN Biosciences, a clinical–stage company with a pipeline of different oncolytic immuno-oncology products, will present clinical data obtainedwith its lead candidate VCN-01 in patients with pancreatic carcinoma at the upcoming annual meeting of the European Society of Medical Oncology (ESMO) in Barcelona, 27 September –1 October2019.
May 6, 2019 – VCN Biosciences, a clinical–stage company developing oncolytic immuno-oncology products today announced that Manel Cascallo, Chief Executive Officer, will present at the following upcoming investor conferences:
January, 2019 -A team of researchers from SJD Barcelona Children’s Hospital has developed a new experimental treatment for retinoblastoma or tumour of the retina, a disease that accounts for 11% of malignancies in children under one year old. The treatment consists of injecting a genetically modified virus into the eye affected by the tumour.
January, 2019 –VCN Biosciences, a clinical–stage company developing oncolytic immuno-oncology products, is pleased toannounce that a Phase 1 trial investigating its product VCN-01in combination with Durvalumab (MEDI4736),Astra-Zeneca’s anti-PD-L1 therapy,has recently obtained regulatory approval.
November, 2016 – VCN Biosciences, a clinical –stage company developing oncolytic immunoncology products, is pleased to announce that preliminary clinical data on the Fist-in-Man Phase 1 clinical trial of VCN-01 after a single intravenous injection, either alone or combined with nab-paclixatel/gemcitabine will be presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, one of the world foremost oncology conferences on the latest developments in targets and drugs for cancer.
Fabruary, 2016 -After evaluating the safety and tolerability of the systemic administration of VCN-01 in monotherapy in P-VCNA-001 Phase 1 trial, Part II of this study is designed to determine the safety and biological activity of combining VCN-01 and chemotherapy (gemcitabine and Abraxane®).
February, 2016 -A consortium led by VCN Biosciencesreceives funding for Cure4RBproject (RTC-2015-4319-1)by Ministerio de Economía y Competitividad (MINECO)from Spanish Government, programRETOS DE COLABORACIÓN -2015.
May 2014. VCN Biosciences has announced that it has initiated its two first clinical studies examining the use of VCN-01in patients with cancer.
VCN Biosciences' new facilities at Grifols Corporate Offices.
July, 2013 -VCN Biosciences was invited to present its recent results on the chemosensitization capabilities to gemcitabine of its lead candidate VCN-01 in the framework of the 7th edition of the International Meeting On Replicating Oncolytic Virus Therapeutics, that was held during June 15th to 18th in Old Quebec City, Quebec (Canada).
July, 2013 -The Spanish Office for Patents and Trademarks (OEMPS) granted a patent (ES23852251 B1) entitled “Adenovirus oncolíticos para el tratamiento del cancer”. The claims cover oncolytic adenoviruses expressing hyaluronidase enzyme to enhance its antitumoral efficacy.
October, 2012 -VCN Biosciences technologies will be again present (from 26th to 29th ofOctober 2012) in the 20th Annual Meeting of the European Society of Geneand Cell Therapy (ESTCG) that this year is organized in collaboration withthe French Society of Gene and Cell Therapy (SFCGT) in Versailles (France).
July, 2012 -Grifols group enters VCN Biosciences aquiring equity shares and warrants the development of therapeutic candidates of the company.
June, 2012 -One year more VCN Biosciences will be present in the Bio International Convention 2012 to be held in Boston from June 18th to 21th, 2012.
May 2012 -VCN Biosciences, a company specialized in the development of new biotechnological products for the treatment of cancer, completed last winter a round of consultation with the European Medicines Agency (EMA) and the Spanish Medicines Authorities (AEMPS) to discuss the proposed development for VCN-01, its most advanced candidate for treatment of pancreatic cancer.
October, 2011 -VCNBiosciences and Genoma España closed last June an agreement which provides VCN Biosciences additional funding for the development of its portfolio of products for the treatment of cancers resistant to chemotherapy.
June, 2011. -VCN Biosciences, a catalan biotechcompany focused in the development of new antitumoral agents for the treatment of human tumors that lack effective therapy, has recently obtained the granting for Orphan Medicinal Product for its more advanced clinical candidate VCN-01 in the treatment of human pancreatic carcinoma by the Committee for Orphan Medicinal Products (COMB) from EMA (European Medicines Agency).
June, 2011 -VCN Biosciences will participate in the forthcoming edition of theBio International Conventionto be held in Washington D.C. fromJune 27th to 30th, 2011.
January, 2011 -VCN Biosciences appears in the January 2011 issue of the supplement “+Innovació” on new business ideas from El Pediódico.
November, 2010 -Biocentury (the Bernstein Report on BioBusiness) publishes in its issue form Novembre 15th, 2010 a report on VCN in its “Emerging Company profile” section: “VCN anti-tumor Ad-vantages” .
October, 2010 -VCN is invited to present data on VCN-01 at the Congreso Oncológico Ciudad de Benavente (Zamora).
July, 2010 - “ORCA Therapeutics B.V. a biopharmaceutical company in the field of virotherapy, today announced that it obtained an exclusive license from VCN Biosciences L.S. in Gelida (Barcelona), Spain, to their T1 oncolytic adenovirus technology for the treatment of cancer.
© Copyright 2022 VCNBiosciences